Finance

Lists
4565:TYO
Nxera Pharma Co Ltd
Â¥1,104.00
-0.09%
(-1.00) 1D
Aug 17, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4565...
Open
Â¥1,108
High
Â¥1,157
Low
Â¥1,096
Mkt. cap
102.25B
Avg. vol.
749.63K
Volume
1.03M
52-wk high
Â¥1,247
52-wk low
Â¥723
EPS
-Â¥86
Shares outstanding
76.30M
No. of employees
322
Open
Â¥1,108
High
Â¥1,157
Low
Â¥1,096
Mkt. cap
102.25B
Avg. vol.
749.63K
Volume
1.03M
52-wk high
Â¥1,247
52-wk low
Â¥723
EPS
-Â¥86
Shares outstanding
76.30M
No. of employees
322
About Nxera Pharma Co Ltd
CEO-
Employees322
FoundedJun 22, 1990
Headquarters-
SectorPharmaceutical industry
Websitenxera.life
Last report
Aug 7, 2026
Fiscal period
Q2 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
7.65B / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
6.75B
7.77B
11.26B
7.65B
Cost of goods sold
2.67B
2.05B
1.12B
2.16B
Cost of revenue
2.67B
2.05B
1.12B
2.16B
Research and development expenses
3.73B
3.27B
3.03B
2.97B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.84B
363.00M
3.57B
3.38B
Operating expense
7.23B
8.08B
6.89B
6.85B
Total operating expenses
9.90B
10.13B
8.01B
9.02B
Operating income
-3.15B
-2.36B
3.24B
-1.36B
Other non operating income
-
-5.02B
-2.00M
2.00M
EBT including unusual items
-3.12B
-8.11B
3.04B
-1.64B
EBT excluding unusual items
-3.12B
-6.30B
3.04B
-1.64B
Income tax expense
-1.44B
-391.00M
1.25B
-1.44B
Effective tax rate
46.34%
4.82%
41.08%
87.71%
Other operating expenses
-338.00M
996.00M
295.00M
499.00M
Net income
-1.67B
-7.72B
1.79B
-202.00M
Net profit margin
-24.76%
-99.41%
15.93%
-2.64%
Earnings per share
-
-
-
-
Interest and investment income
239.00M
1.06B
144.00M
-
Interest expense
-204.00M
-
-287.00M
-488.00M
Net interest expenses
35.00M
1.06B
-143.00M
-488.00M
Depreciation and amortization charges
-
3.45B
-
-
EBITDA
-2.04B
-1.28B
4.35B
-268.00M
Gain or loss from assets sale
-
1.16B
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps